Sign In
Buy VOR
$13.44
-0.220 (-1.61%)
At Close: Jun 03, 2026
Head to Head Analysis: Liminatus Pharma (NASDAQ:LIMN) versus Vor Biopharma (NASDAQ:VOR)
05:22am, Sunday, 16'th Nov 2025
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Vor Biopharma (NASDAQ: VOR - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two b
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:01pm, Thursday, 13'th Nov 2025
Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune Diseases Expansion of Executive Leadership and Board Strengthens Global Development Capabilities
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial
09:43am, Tuesday, 11'th Nov 2025
Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share.
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
09:56pm, Monday, 10'th Nov 2025
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the p
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
04:01pm, Monday, 10'th Nov 2025
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today annou
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
11:45am, Saturday, 08'th Nov 2025
Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile
Vor Bio to Participate in Upcoming Investor Conferences
08:00am, Friday, 07'th Nov 2025
BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in t
/PRNewswire/ -- ACTO, ein führender Anbieter von KI-gestützten Spitzenlösungen für die Biowissenschaften, Veeva-Produktpartner und Mitglied des Veeva
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
08:00am, Monday, 03'rd Nov 2025
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sok
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 31'st Oct 2025
BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, th
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activ
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease
04:30pm, Wednesday, 22'nd Oct 2025
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data
Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-
